Advaxis (OTCMKTS:ADXS) Share Price Crosses Above 200 Day Moving Average of $0.00
Advaxis (OTCMKTS:ADXS) Share Price Crosses Above 200 Day Moving Average of $0.00
Advaxis, Inc. (OTCMKTS:ADXS – Get Rating)'s stock price crossed above its two hundred day moving average during trading on Monday . The stock has a two hundred day moving average of $0.00 and traded as high as $3.47. Advaxis shares last traded at $3.06, with a volume of 1,068 shares traded.
Advaxis,Inc.(OTCMKTS:ADXS-GET Rating)的股价在周一的交易中突破了200日移动均线,200日移动均线为0.00美元,最高交易价格为3.47美元。Advaxis的股票最新报3.06美元,成交量为1,068股。
Wall Street Analysts Forecast Growth
华尔街分析师预测经济增长
Separately, StockNews.com started coverage on shares of Advaxis in a research report on Monday, August 22nd. They issued a "sell" rating on the stock.
另外,StockNews.com在8月22日星期一的一份研究报告中开始对Advaxis的股票进行报道。他们对这只股票发布了“卖出”评级。
Advaxis Stock Up 0.3 %
Advaxis股价上涨0.3%
The firm has a 50-day moving average of $3.57. The stock has a market capitalization of $5.56 million, a P/E ratio of -30.60 and a beta of 2.07.
该公司的50日移动均线切入位为3.57美元。该股市值556万美元,市盈率为-30.60,贝塔系数为2.07。
About Advaxis
关于Advaxis
Advaxis, Inc, a clinical-stage biotechnology company, focuses on the discovery, development, and commercialization of proprietary Listeria monocytogenes (Lm) technology antigen delivery products in the United States. The company is developing ADXS-PSA, which is in Phase 2 clinical trials for the treatment of metastatic prostate cancer; ADXS-503 that is in Phase 1/2 clinical trials for the treatment of non-small cell lung cancer; and ADXS-504 for the treatment of prostate cancer.
Advaxis,Inc.是一家临床阶段的生物技术公司,专注于在美国发现、开发和商业化专有的单核细胞增生性李斯特菌(LM)技术抗原递送产品。该公司正在开发ADXS-PSA,这是用于治疗转移性前列腺癌的第二阶段临床试验;ADXS-503,用于治疗非小细胞肺癌;以及ADXS-504,用于治疗前列腺癌。
Recommended Stories
推荐故事
- Get a free copy of the StockNews.com research report on Advaxis (ADXS)
- Darden Restaurants Takes the Low Road Against Inflation
- Why These 3 Stocks Are Off to Hot September Starts
- Inflation Doesn't Differentiate, But it's Impact Does
- 3 Downgraded Must-Have Stocks To Put On Your Watchlist
- This Is What To Expect From The Q3 Earnings Reporting Season
- 免费获取StockNews.com关于Advaxis的研究报告(ADXS)
- 达顿餐厅走低通胀之路
- 这3只股票为何在9月火爆开盘
- 通货膨胀没有差别,但它的影响有差别
- 3只被降级的必备股票放在你的观察名单上
- 这是对第三季度收益报告季节的预期
Receive News & Ratings for Advaxis Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Advaxis and related companies with MarketBeat.com's FREE daily email newsletter.
接受Advaxis Daily的新闻和评级-在下面输入您的电子邮件地址,通过MarketBeat.com的免费每日电子邮件时事通讯接收对Advaxis和相关公司的最新新闻和分析师评级的每日简要摘要。